9 April 2019 - TAKIS announces a collaboration partnership with TRIANNI
Rome, April 9, 2019 - Takis S.r.l. (“TAKIS”) and Trianni, Inc. ("TRIANNI") today announced Takis access to the Trianni mice platform as service provider.
TAKIS is proud to announce that the Company can now offer antibody generation services to using the Trianni Mouse™. TRIANNI is a biotech company specialized in antibody discovery technology and TAKIS is now able to provide fully human monoclonal antibodies for Clients that hold a license for the use of the Trianni mouse.
TRIANNI’s lead technology, The Trianni Mouse™ enables efficient generation of fully-human monoclonal antibodies. TRIANNI's transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology making it a best-in-class therapeutic antibody discovery platform.
Dr Giuseppe Roscilli, Director of the Antibody Department at Takis, stated: “Takis has a thorough experience in the development of custom monoclonal antibodies and the Trianni Mouse integration with our antibody generation technologies, especially with in vivo electro-gene-transfer of plasmid DNA (DNA-EGT) vaccination system, allows to provide our worldwide customers with an efficient platform for the discovery and development of fully human antibodies”.
Dr. Luigi Aurisicchio, CEO of Takis, stated: "We are happy to be chosen by Trianni for antibody discovery services. With the aim to offer best-in-class services to our Clients, Takis has been looking for technologies that would allow the efficient generation of humanized antibody. The Trianni Mouse is a unique platform to develop fully human monoclonal antibodies and it is now an integral component of our service portfolio."
"We are pleased to have Takis provide services using the Trianni mouse" stated Matthias Wabl, Ph.D., Chairman and CEO of TRIANNI. "This collaboration allows Customers that have a license for the Trianni platform to access the Takis expertise and vaccination technologies”.
About Takis S.r.l.
Takis is a privately held organization, founded in 2009 by former Merck Research Laboratories employees. The group has more than 15 years of experience and an established track record in drug discovery in Oncology and is recognized for the conception and implementation of a number of innovative technologies. One of the main assets of Takis is the expertise in in vivo Electro-Gene-Transfer (DNA-EGT), which can be used for a variety of clinically useful applications, from vaccine development to somatic gene therapy to antibody development. Takis pipeline include four Cancer Vaccine candidates based on this technology. Takis is actively involved in the generation of humanized monoclonal antibodies for use in Oncology and Infectious Diseases. Takis operates worldwide as a Contract Research Organization providing the highest quality and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery. Takis has established multiple service and discovery agreements with Biotech and Pharma partners, among them Alfasigma and Italfarmaco in Oncology and inflammatory diseases, Incyte and Boehringer Ingelheim for Immune-Oncology, Johnson & Johnson’s for Immunology, Glaxo-Smith-Kline for Antibody generation. For additional information please go to www.takisbiotech.it.
About Trianni, Inc.
Trianni is a privately held organization, formed in 2010 with a mission to use recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company has research and administrative facilities in the San Francisco Bay Area (CA, USA) and in Research Triangle Park (NC, USA). For more information, please visit www.trianni.com.
Giuseppe Roscilli, PhD
Director, Monoclonal Antibody Department
Director of Marketing
SOURCE Takis S.r.l. (www.takisbiotech.it)